Gland Pharma Delivers Robust FY26 Performance, Recommends ₹20 Dividend

Gland Pharma reported consolidated revenue from operations of ₹64,307 million for the financial year ended March 31, 2026, a 14.5% increase from ₹56,165 million in FY25. Adjusted Profit After Tax (PAT) surged by 49.7% to ₹10,455 million from ₹6,985 million in the previous fiscal year.

Reader Takeaway: Profit growth driven by US launches; forward-looking risks persist.

What just happened (today’s filing)

The company's Board of Directors met on May 15, 2026, approving the audited financial results for FY26. Gland Pharma recommended a final dividend of ₹20 per equity share.

This strong financial performance was supported by significant operational progress. In Q4 FY26, Gland Pharma launched five new molecules in the crucial USA market, including Dalbavancin and Brimonidine.

The company also saw robust activity in its US regulatory filings, submitting 8 ANDAs and securing 11 approvals during Q4 FY26. Cumulatively, this brings its US filing total to 388 with 337 approvals.

Further bolstering its business pipeline, Gland Pharma signed a new CDMO contract for a complex Nano Drug Delivery System-based injectable in the oncology segment. R&D expenses for Q4 FY26 were ₹506 million, focused on developing complex products.

Why this matters

The substantial increase in revenue and profit, coupled with a recommended dividend, underscores Gland Pharma's improved operational efficiency and market execution. The company's strategic focus on new molecule launches and expanding its CDMO services appears to be yielding positive financial results.

This performance reflects the company's ability to navigate the competitive pharmaceutical landscape and leverage its manufacturing and development capabilities. Shareholder returns through dividends further enhance the appeal of the stock.

The backstory (grounded)

Gland Pharma is a leading generic injectables manufacturer in India, with a significant focus on the US market. It offers sterile injectables, oncology, and complex injectable products, alongside contract development and manufacturing (CDMO) services.

Over the last 24 months, Gland Pharma has been actively launching new molecules in the US, focusing on expanding its ANDA filings and approvals. The company has emphasized its R&D capabilities for complex generics and its CDMO business.

What changes now

Shareholders are set to benefit from a recommended final dividend of ₹20 per equity share, pending AGM approval.

The company's financial health has visibly improved, with strong growth in both top-line revenue and bottom-line profit.

Its US market presence is strengthening through new product launches and regulatory approvals, alongside expansion in the high-margin CDMO segment.

Risks to watch

The presentation accompanying the results may contain forward-looking statements. These are subject to various risks and uncertainties, including general economic conditions, competition, and regulatory or technological changes.

Peer comparison

Dr. Reddy's Laboratories and Cipla have also focused on expanding their US generics presence and complex product pipelines, indicating a competitive but growing market.

Divi's Laboratories, a major CDMO partner for global pharma companies, highlights the broader trend of contract manufacturing growth in the Indian pharmaceutical sector.

Context metrics (time-bound)

• Consolidated Revenue from Operations grew from ₹56,165 million in FY25 to ₹64,307 million in FY26.
• Consolidated Adjusted PAT increased from ₹6,985 million in FY25 to ₹10,455 million in FY26.

What to track next

Shareholder approval for the recommended final dividend at the upcoming Annual General Meeting (AGM).

Timely payment of the dividend within 30 days from the date of the 48th AGM.

Future performance of the five molecules launched in the USA in Q4 FY26.

Continued progress in ANDA filings and approvals for the US market.

Developments in the CDMO pipeline and secured contracts, particularly for complex injectables.